HYTERA-COMMUNICATIONS
15.5.2023 12:55:30 CEST | Business Wire | Press release
Hytera Communications (SZSE: 002583), a leading global provider of professional communications technologies and solutions, gathered its distribution, project, and application partners from over 50 countries and regions and successfully held Hytera Global Partner Summit (HGPS) 2023 on May 11th in Bali, Indonesia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005390/en/
Yelin Jiang, CEO of Hytera Group, delivering the keynote speech (Photo: Business Wire)
HGPS serves as a platform for Hytera partners to network with other like-minded professionals, gain insights into the latest trends of the industry, and learn what’s new with Hytera, including new products, solutions, and policies. The year 2023 marks the 30th anniversary of the company; therefore, HGPS 2023 was also a venue for the retrospect and celebration of the common journey shared by Hytera and its partners from across the world.
“The past 30 years have seen Hytera rose against numerous challenges and evolved from a product provider to a technology and solution provider. Now we are one of the leading companies in mission-critical and business-critical communications. Our talented engineers working in 8 R&D facilities across the world are the source of our confidence in future growth,” said Yelin Jiang, CEO of Hytera Group, in the keynote speech. “In 2022, Hytera released many innovative new products across multiple product series such as DMR radios, MCS & PoC radios, and body cameras. The new-generation H Series DMR radio was an instant success in the market.”
Thomas Lynch, executive research director of Omdia, was present to share the latest industry trends and developments with attendees, providing insights into the ever-changing industry landscape. According to Omdia’s analysis, in response to the market demands for data-rich features, Mission Critical Communications are moving towards a hybrid approach: keeping trusted LMR technology, such as TETRA, DMR, PDT for the indispensable voice communication in extreme situations and empowering the additional services and features with integrated LTE Broadband solutions. This is manifested in Hytera’s multi-front product development strategy.
Fully leveraging the venue of HGPS, Hytera brought regional partners into a global perspective with product solution deep dives and partners’ case studies. At the exhibition area, a complete portfolio of Hytera products and solutions were showcased, including TETRA Radios and Systems, DMR Radios and Systems, MCS & PoC Radios and Solutions, Body Camera Solutions, Multimedia Communication Platform, Control Room Solutions, 4G&5G Systems, and Fast Deployment Solutions. HGPS2023 invited some of Hytera ecosystem partners to showcase their value-added applications on top of Hytera products and they brought solutions such as encryptions, dispatching, satellite connectivity, and emergency coordination.
The Summit concluded on a high note with the Hytera 30th Anniversary and Awarding Ceremony, which acknowledged the performance and progress of partners in the year 2022. Golden Loyalty Awards was specially set up for HGPS2023 to celebrate the long-term partnership with and loyalty to the Hytera brand in the past three decades.
About Hytera
Hytera Communications Corporation Limited (SZSE: 002583) is a leading global provider of professional communications technologies and solutions. With voice, video and data capabilities, we provide faster, safer, and more versatile connectivity for business and mission critical users. We make the world more efficient and safer by enabling our customers to achieve more in both daily operations and emergency response. Learn more at https://www.hytera.com/en/home.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005390/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom